Oncology Institute, Inc. (TOI) Cash & Equivalents (2019 - 2026)

Oncology Institute (TOI) has 8 years of Cash & Equivalents data on file, last reported at $30.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 23.8% year-over-year to $30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (down 23.8% YoY) and the FY2025 annual result came in at $33.6 million, down 32.42% from the prior year.
• Cash & Equivalents fell to $30.3 million in Q1 2026, from $33.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $95.5 million in Q1 2022 to a low of $14.0 million in Q4 2022.
• A 5-year average of $39.5 million and a median of $33.6 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 432.65% in 2022, down 87.84% in 2022.
• Tracing TOI's Cash & Equivalents over 5 years: stood at $14.0 million in 2022, then surged by 139.03% to $33.5 million in 2023, then jumped by 48.32% to $49.7 million in 2024, then slumped by 32.42% to $33.6 million in 2025, then dropped by 9.79% to $30.3 million in 2026.
• The last three Cash & Equivalents figures came in at $30.3 million (Q1 2026), $33.6 million (Q4 2025), and $27.7 million (Q3 2025), per Business Quant data.